All Stories

  1. Dopamine D1 receptors mediate methamphetamine-induced dopaminergic damage: involvement of autophagy regulation via the AMPK/FOXO3A pathway
  2. Dysregulation of iron homeostasis and methamphetamine reward behaviors in Clk1-deficient mice
  3. Inhibition of neuroinflammation by MIF inhibitor 3-({[4-(4-methoxyphenyl)-6-methyl-2-pyrimidinyl]thio}1methyl)benzoic acid (Z-312)
  4. Sigma-1 receptor regulates mitophagy in dopaminergic neurons and contributes to dopaminergic protection
  5. Discovery of novel MIF inhibitors that attenuate microglial inflammatory activation by structures-based virtual screening and in vitro bioassays
  6. Early glycolytic reprogramming controls microglial inflammatory activation
  7. Glycoproteins as diagnostic and prognostic biomarkers for neurodegenerative diseases: A glycoproteomic approach
  8. Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases
  9. PHLDA1 promotes microglia-mediated neuroinflammation via regulating K63-linked ubiquitination of TRAF6
  10. Protective Effect of Metformin against Hydrogen Peroxide-Induced Oxidative Damage in Human Retinal Pigment Epithelial (RPE) Cells by Enhancing Autophagy through Activation of AMPK Pathway
  11. Knockdown of milk‐fat globule EGF factor‐8 suppresses glioma progression in GL261 glioma cells by repressing microglial M2 polarization
  12. Emerging novel approaches to drug research and diagnosis of Parkinson’s disease
  13. Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson’s disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin
  14. C9orf72 associates with inactive Rag GTPases and regulates mTORC1‐mediated autophagosomal and lysosomal biogenesis
  15. Developmental Genes and Regulatory Proteins, Domains of Cognitive Impairment in Schizophrenia Spectrum Psychosis and Implications for Antipsychotic Drug Discovery: The Example of Dysbindin-1 Isoforms and Beyond
  16. FoxO3a suppresses neuropeptide W expression in neuronal cells and in rat hypothalamus and its implication in hypothalamic-pituitary-adrenal (HPA) axis
  17. Absence of TRIM32 Leads to Reduced GABAergic Interneuron Generation and Autism-like Behaviors in Mice via Suppressing mTOR Signaling
  18. D2 receptor-mediated miRNA-143 expression is associated with the effects of antipsychotic drugs on phencyclidine-induced schizophrenia-related locomotor hyperactivity and with Neuregulin-1 expression in mice
  19. The oncometabolite 2-hydroxyglutarate inhibits microglial activation via the AMPK/mTOR/NF-κB pathway
  20. Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases
  21. Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson’s Disease: A Recent Update and Challenge
  22. Emerging and evolving concepts in the pathobiology and treatment of psychosis
  23. Dysregulation of miRNA and its potential therapeutic application in schizophrenia
  24. Macrophage migration inhibitory factor (MIF) inhibitor, Z-590 suppresses cartilage destruction in adjuvant-induced arthritis via inhibition of macrophage inflammatory activation
  25. miRNA-3473b contributes to neuroinflammation following cerebral ischemia
  26. Dihydromyricetin exerts a rapid antidepressant-like effect in association with enhancement of BDNF expression and inhibition of neuroinflammation
  27. Activation of AMPK/mTORC1-Mediated Autophagy by Metformin Reverses Clk1 Deficiency-Sensitized Dopaminergic Neuronal Death
  28. Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies
  29. Clk1-regulated aerobic glycolysis is involved in glioma chemoresistance
  30. Prediction of chemical biodegradability using computational methods
  31. Dihydromyricetin protects against cerebral ischemia/reperfusion injury via suppressing microglia-mediated neuroinflammation and activation of ERK1/2-CREB signaling pathway
  32. Discovery of Novel and Selective Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease through Comparative Structure-Based Virtual Screening
  33. Erratum: Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity
  34. Design and optimization of purine derivatives as in vivo active PDE10A inhibitors
  35. Clk1 deficiency promotes neuroinflammation and subsequent dopaminergic cell death through regulation of microglial metabolic reprogramming
  36. Activation of Nur77 in microglia attenuates proinflammatory mediators production and protects dopaminergic neurons from inflammation-induced cell death
  37. GSK-3βInteracts with Dopamine D1 Receptor to Regulate Receptor Function: Implication for Prefrontal Cortical D1 Receptor Dysfunction in Schizophrenia
  38. Phosphodiesterase 10A inhibition attenuates sleep deprivation-induced deficits in long-term fear memory
  39. Identification of a New Series of Potent Adenosine A2A Receptor Antagonists Based on 4-Amino-5-carbonitrile Pyrimidine Template for the Treatment of Parkinson’s Disease
  40. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity suppresses microglia-mediated inflammatory responses
  41. GSK-3β inhibitors reverse cocaine-induced synaptic transmission dysfunction in the nucleus accumbens
  42. Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity
  43. Functional reversal of (−)-Stepholidine analogues by replacement of benzazepine substructure using the ring-expansion strategy
  44. LLDT-8 protects against cerebral ischemia/reperfusion injury by suppressing post-stroke inflammation
  45. Morphine-induced inhibition of Ca2+ -dependent d -serine release from astrocytes suppresses excitability of GABAergic neurons in the nucleus accumbens
  46. Accessible Method for the Development of Novel Sterol Analogues with Dipeptide-like Side Chains That Act as Neuroinflammation Inhibitors
  47. Allosteric Modulation of Sigma-1 Receptors Elicits Rapid Antidepressant Activity
  48. Mice heterozygous for cathepsin D deficiency exhibit mania-related behavior and stress-induced depression
  49. MicroRNA let-7c-5p protects against cerebral ischemia injury via mechanisms involving the inhibition of microglia activation
  50. Structure–Activity Relationships and Anti-inflammatory Activities ofN-Carbamothioylformamide Analogues as MIF Tautomerase Inhibitors
  51. Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold
  52. Higher-Affinity Agonists of 5-HT1AR Discovered through Tuning the Binding-Site Flexibility
  53. Prefrontal cortex gates acute morphine action on dopamine neurons in the ventral tegmental area
  54. Protease Omi facilitates neurite outgrowth in mouse neuroblastoma N2a cells by cleaving transcription factor E2F1
  55. Neuropharmacological Actions of Metformin in Stroke
  56. Allosteric modulation of sigma-1 receptors elicits anti-seizure activities
  57. Allosteric modulation of sigma-1 receptors by SKF83959 inhibits microglia-mediated inflammation
  58. Anti-inflammatory effects of glaucocalyxin B in microglia cells
  59. Design, synthesis and evaluation of a series of non-steroidal anti-inflammatory drug conjugates as novel neuroinflammatory inhibitors
  60. Induction of COX-2-PGE2 synthesis by activation of the MAPK/ERK pathway contributes to neuronal death triggered by TDP-43-depleted microglia
  61. Glial Pathology in Bipolar Disorder: Potential Therapeutic Implications
  62. Inhibition of Neuroinflammation by Synthetic Androstene Derivatives Incorporating Amino Acid Methyl Esters on Activated BV-2 Microglia
  63. Sigma-2 Receptor Ligands: Neurobiological Effects
  64. Absorption, Distribution, Metabolism, Excretion, and Toxicity Evaluation in Drug Discovery. 14. Prediction of Human Pregnane X Receptor Activators by Using Naive Bayesian Classification Technique
  65. Discovery of 4-benzoylpiperidine and 3-(piperidin-4-yl)benzo[d]isoxazole derivatives as potential and selective GlyT1 inhibitors
  66. Rotenone impairs autophagic flux and lysosomal functions in Parkinson’s disease
  67. Naja naja atra venom ameliorates pulmonary fibrosis by inhibiting inflammatory response and oxidative stress
  68. A Computational Perspective on Drug Discovery and Signal Transduction Mechanism of Dopamine and Serotonin Receptors in the Treatment of Schizophrenia
  69. Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles
  70. Assessing an Ensemble Docking-Based Virtual Screening Strategy for Kinase Targets by Considering Protein Flexibility
  71. CaMKKβ-Dependent Activation of AMP-Activated Protein Kinase Is Critical to Suppressive Effects of Hydrogen Sulfide on Neuroinflammation
  72. Structural manipulation on the catecholic fragment of dopamine D1 receptor agonist 1-phenyl-N-methyl-benzazepines
  73. Inhibition of phosphodiesterase10A attenuates morphine-induced conditioned place preference
  74. ChemInform Abstract: Topsendines A-F, New 3-Alkylpyridine Alkaloids from a Hainan Sponge Topsentia sp.
  75. (6aR)-11-Amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease
  76. Optimization of 6-Heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as Potent Adenosine A2AReceptor Antagonists for the Treatment of Parkinson’s Disease
  77. Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke
  78. Effects of SKF83959 on the excitability of hippocampal CA1 pyramidal neurons: a modeling study
  79. Discovery of Novel Inhibitors Targeting the Macrophage Migration Inhibitory Factor via Structure-Based Virtual Screening and Bioassays
  80. Topsendines A–F, new 3-alkylpyridine alkaloids from a Hainan sponge Topsentia sp.
  81. Robo3.1A suppresses Slit-mediated repulsion by triggering degradation of Robo2
  82. Mutation of SLC35D3 Causes Metabolic Syndrome by Impairing Dopamine Signaling in Striatal D1 Neurons
  83. Synthesis of 5α-cholestan-6-one derivatives and their inhibitory activities of NO production in activated microglia: Discovery of a novel neuroinflammation inhibitor
  84. Inhibition of phosphodiesterase10A attenuates morphine-induced conditioned place preference
  85. Antiinflammatory Effects of Orientin-2″-O-Galactopyranoside on Lipopolysaccharide-Stimulated Microglia
  86. 1-O-Tigloyl-1-O-deacetyl-nimbolinin B Inhibits LPS-Stimulated Inflammatory Responses by Suppressing NF-κB and JNK Activation in Microglia Cells
  87. Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists
  88. Molecular Modeling of the 3D Structure of 5-HT1AR: Discovery of Novel 5-HT1AR Agonists via Dynamic Pharmacophore-Based Virtual Screening
  89. Postischemic Administration of a Potent PTEN Inhibitor Reduces Spontaneous Lung Infection Following Experimental Stroke
  90. Synthesis, preliminary pharmacological evaluation and receptor docking studies of 10-amino-3-methoxy-6,8,12,12a-tetrahydro-5H-thiazolo[4',5':4,5]pyrido[2,1-a]isoquinolin-2-ols as novel dopamine D1 receptor inhibitors
  91. Design, Synthesis, and Evaluation of Indolebutylamines as a Novel Class of Selective Dopamine D3 Receptor Ligands
  92. SKF83959 is a novel triple reuptake inhibitor that elicits anti-depressant activity
  93. Current developments of macrophage migration inhibitory factor (MIF) inhibitors
  94. Differential mechanisms underlying neuroprotection of hydrogen sulfide donors against oxidative stress
  95. Update 1 of: Recent Progress in Development of Dopamine Receptor Subtype-Selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders
  96. Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D1, D2 and serotonin 5-HT1A multi-action profile
  97. Delayed administration of a PTEN inhibitor BPV improves functional recovery after experimental stroke
  98. CMYA5: a new potential substrate of Kcna3 in human heart
  99. SKF83959 Is a Potent Allosteric Modulator of Sigma-1 Receptor
  100. Methylphenidate Enhances NMDA-Receptor Response in Medial Prefrontal Cortex via Sigma-1 Receptor: A Novel Mechanism for Methylphenidate Action
  101. GABA Neurons in the Ventral Tegmental Area Responding to Peripheral Sensory Input
  102. Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: Selective inhibitors of dopamine D1 receptor
  103. Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors
  104. Generation and characterization of hD5 and C-terminal Mutant hD5m transgenic rats
  105. L166P mutant DJ-1 promotes cell death by dissociating Bax from mitochondrial Bcl-XL
  106. PSD-95 Interacts with Dopamine D1-Receptor: Functional Implication
  107. Identification ofN-Propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl)pentanoate as a New Anti-Parkinson's Agent Possessing a Dopamine D2and Serotonin 5-HT1ADual-Agonist Profile
  108. SKF83959 suppresses excitatory synaptic transmission in rat hippocampus via a dopamine receptor-independent mechanism
  109. The Retardation of Myometrial Infiltration, Reduction of Uterine Contractility, and Alleviation of Generalized Hyperalgesia in Mice With Induced Adenomyosis by Levo-Tetrahydropalmatine (l-THP) and Andrographolide
  110. Further SAR study on 11-O-substituted aporphine analogues: Identification of highly potent dopamine D3 receptor ligands
  111. Levo-Tetrahydropalmatine Retards the Growth of Ectopic Endometrial Implants and Alleviates Generalized Hyperalgesia in Experimentally Induced Endometriosis in Rats
  112. Tetrahydroberberine blocks ATP-sensitive potassium channels in dopamine neurons acutely-dissociated from rat substantia nigra pars compacta
  113. Electrophysiological Effects of SKF83959 on Hippocampal CA1 Pyramidal Neurons: Potential Mechanisms for the Drug's Neuroprotective Effects
  114. l-Stepholidine-induced excitation of dopamine neurons in rat ventral tegmental area is associated with its 5-HT1A receptor partial agonistic activity
  115. Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels in the regulation of midbrain dopamine systems
  116. Activation of phosphatidylinositol-linked D1-like receptors increases spontaneous glutamate release in rat somatosensory cortical neurons in vitro
  117. l-Stepholidine reduced l-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease
  118. Synthesis of Dihydrofuroaporphine Derivatives: Identification of a Potent and Selective Serotonin 5-HT1AReceptor Agonist
  119. Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand
  120. ‘Click’ D1 receptor agonists with a 5-HT1A receptor pharmacophore producing D2 receptor activity
  121. Activation of Phosphatidylinositol-Linked D1-Like Receptor Modulates FGF-2 Expression in Astrocytes via IP3-Dependent Ca2+ Signaling
  122. Arylbenzazepines Are Potent Modulators for the Delayed Rectifier K+ Channel: A Potential Mechanism for Their Neuroprotective Effects
  123. ChemInform Abstract: Dopamine D1Receptor Ligands: Where Are We Now and Where Are We Going
  124. PSD-95 regulates D1 dopamine receptor resensitization, but not receptor-mediated Gs-protein activation
  125. Dopamine D1receptor ligands: Where are we now and where are we going
  126. Distinctive nicotinic acetylcholine receptor functional phenotypes of rat ventral tegmental area dopaminergic neurons
  127. Limonoids from the Twigs and Leaves ofChukrasia tabularis
  128. Dysbindin deficiency in sandy mice causes reduction of snapin and displays behaviors related to schizophrenia
  129. Synthesis of 6-substituted 1-phenylbenzazepines and their dopamine D1 receptor activities
  130. Single Dose of Morphine Produced a Prolonged Effect on Dopamine Neuron Activities
  131. N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D2 and serotonin 5-HT1A receptor dual ligands
  132. Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines
  133. The effectiveness of carbamazepine in unipolar depression: A double-blind, randomized, placebo-controlled study
  134. Estrogen regulates responses of dopamine neurons in the ventral tegmental area to cocaine
  135. Neuroprotective effects of atypical D1receptor agonist SKF83959 are mediated via D1receptor-dependent inhibition of glycogen synthase kinase-3β and a receptor-independent anti-oxidative action
  136. Recent Developments in Studies of l-Stepholidine and its Analogs: Chemistry, Pharmacology and Clinical Implications
  137. Differential effects of classical and atypical antipsychotic drugs on rotenone-induced neurotoxicity in PC12 cells
  138. Recent Development in Studies of Tetrahydroprotoberberines: Mechanism in Antinociception and Drug Addiction
  139. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease
  140. Effects of (-)-stepholidine on NMDA receptors: comparison with haloperidol and clozapine
  141. Requirement of PSD-95 for dopamine D1receptor modulating glutamate NR1a/NR2B receptor function
  142. l-Stepholidine increases the frequency of sEPSC via the activation of D1dopamine signaling pathway in rat prelimbic cortical neurons
  143. Estrogen-modulated frontal cortical CaMKII activity and behavioral supersensitization induced by prolonged cocaine treatment in female rats
  144. Modulation of Ca2+ signals by phosphatidylinositol-linked novel D1 dopamine receptor in hippocampal neurons
  145. The paradoxical effects of SKF83959, a novel dopamine D1-like receptor agonist, in the rat acoustic startle reflex paradigm
  146. The role of the phosphatidyinositol-linked D dopamine receptor in the pharmacology of SKF83959
  147. Regulation of Cyclin-Dependent Kinase 5 and Calcium/Calmodulin-Dependent Protein Kinase II by Phosphatidylinositol-Linked Dopamine Receptor in Rat Brain
  148. Prenatal cocaine exposure alters glycogen synthase kinase-3β (GSK3β) pathway in select rabbit brain areas
  149. SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain
  150. Inhibition of Protein Tyrosine/Mitogen-Activated Protein Kinase Phosphatase Activity Is Associated with D2 Dopamine Receptor Supersensitivity in a Rat Model of Parkinson's Disease
  151. Lithium regulates protein tyrosine phosphatase activity in vitro and in vivo
  152. Prenatal Exposure to Cocaine Disrupts D1ADopamine Receptor Function Via Selective Inhibition of Protein Phosphatase 1 Pathway in Rabbit Frontal Cortex
  153. The p38 Mitogen-Activated Protein Kinase Is Involved in Associative Learning in Rabbits
  154. Osteopontin Gene Regulation by Oscillatory Fluid Flow via Intracellular Calcium Mobilization and Activation of Mitogen-activated Protein Kinase in MC3T3-E1 Osteoblasts
  155. Mitogen-activated Protein Kinase p38 Mediates Regulation of Chondrocyte Differentiation by Parathyroid Hormone
  156. Activation of Extracellular Signal-Regulated Protein Kinases Is Associated with a Sensitized Locomotor Response to D2Dopamine Receptor Stimulation in Unilateral 6-Hydroxydopamine-Lesioned Rats
  157. Age-Associated Impairment in Brain MAPK Signal Pathways and the Effect of Caloric Restriction in Fischer 344 Rats
  158. D1Dopamine Receptor Agonists Mediate Activation of p38 Mitogen-Activated Protein Kinase and c-Jun Amino-Terminal Kinase by a Protein Kinase A-Dependent Mechanism in SK-N-MC Human Neuroblastoma Cells
  159. Platelet-Derived Growth Factor Stimulates Sodium-Dependent Pi Transport in Osteoblastic Cells via Phospholipase Cγ and Phosphatidylinositol 3′-Kinase
  160. Aluminum potentiates P(i) transport stimulation induced by fluoride in osteoblast-like cells